Experience with isolated hepatic perfusion (IHP) is limited to a few centers in the world because of the technical difficulties, surgery-related morbidity, and unproved efficacy in randomized trials. Experimental animal IHP models have led to exploring new ways of improving efficacy, reducing technical difficulties, and minimizing regional and systemic toxicity. Future research should be directed to the identification of suitable biologic or chemotherapeutic agents, defining clinical indications, and development of technical modifications to make it more generally applicable and even repeatable.

Additional Metadata
Keywords Animals, Antineoplastic Agents, Cancer, Chemotherapy, Clinical Trials as Topic, Humans, Liver Neoplasms, Regional Perfusion, antineoplastic agent, bevacizumab, blood clotting disorder, bone marrow suppression, cancer survival, cetuximab, chlormethine, cisplatin, colorectal cancer, drug megadose, drug potentiation, extracorporeal circulation, floxuridine, fluorouracil, folinic acid, hair loss, histamine, human, hyperthermic therapy, interleukin 2, irinotecan, liver cancer, liver failure, liver metastasis, liver perfusion, liver toxicity, malaise, melanoma, melphalan, mitomycin C, nausea, nonhuman, oxaliplatin, review, tumor necrosis factor, vasoactive agent, vein occlusion
Persistent URL dx.doi.org/10.1016/j.soc.2008.04.007, hdl.handle.net/1765/15248
Journal Surgical Oncology Clinics of North America
Citation
Verhoef, C, de Wilt, J.H.W, ten Hagen, T.L.M, & Eggermont, A.M.M. (2008). Isolated Hepatic Perfusion for the Treatment of Liver Tumors: Sunset or Sunrise?. Surgical Oncology Clinics of North America (Vol. 17, pp. 877–894). doi:10.1016/j.soc.2008.04.007